NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in RRMM (IMPEDE)
Updated: Jun 16, 2022
NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (IMPEDE)
Isatuximab in combination with elotuzumab, pomalidomide, and dexamethasone (Isa-EPD)
This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.
Sponsor
Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT04835129
Official Title: A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
First Posted: April 8, 2021
Click here to see details on ClinicalTrials.gov
Drug: Isatuximab (for run-in portion)
Drug: Isatuximab (for expansion)
Drug: Pomalidomide
Drug: Elotuzumab
Drug: Dexamethasone
Locations
United States, Wisconsin
Froedtert Hospital & the Medical College of Wisconsin